Reve Technologies, Inc. Announces Change Of Name To Cantech Holding, Inc. and Its Domicile to Wyoming from Nevada

MONROVIA CA / ACCESSWIRE / June 6, 2016 / Reve Technologies, Inc. BSSP (the "Company" or "Reve") a development stage immunotherapeutic based technology company today announced that it changed its name to Cantech Holding, Inc. and has moved its domicile to Wyoming from Neveda, effective May 27, 2016. In addition to Cantech's new name and domicile in Wyoming, the Company has also unveiled a new corporate identity and website in its latter stages of development, available at www.cantechholding.com.

The Company is proud to launch our new corporate identity as Cantech, which we believe clearly reflects our business strategy. The name represents the fusion of our innovative approach regarding our commitment to improving lives by helping to bring impactful immunotherapeutic treatment(s) to market initially in Mexico for cancer indication.

The name change does not affect the rights of the company's stockholders. The company's common stock will continue to trade under ticker symbol "BSSP" on the OTC Markets system and the Company. The Company in process of obtaining an assignment for a new CUSIP number in connection with the name change, and its submission of a corporate action toward gaining approval regarding a new ticker symbol for the Company as soon as practicable and plans are to announce any effective date for such change in a future release or current report on Form 8-K. Outstanding stock certificates are not affected by the name change and will not need to be exchanged.

About Canteck Pharma, Inc. IPF for Cancer treatment

Immunotherapy has the potential to provide an alternative and/or complementary treatment in combination with other immune base therapy for several types of cancer. The advantage of immunotherapy over radiation and chemotherapy is that it can act specifically against the tumor without causing normal tissue damage. Current data indicates that immune protection against all cancer requires the generation of a potent cellular immune response against a unique tumor antigen expressed by the malignant cell. As a consequence successful immune protection first requires a unique antigen expressed in the tumor cells (tumor specific antigen) and second, an induction of a potent T-cell immune response, targeted to the tumor antigen.

Unfortunately the immune system by itself can't recognize specific tumor antigens and reject them; however recent advances have revealed that certain proteins binding with specific tumor antigens can be recognized by the immune system, this is what IPF does.

IPF proteins attach to tumor antigens, creating super-antigens (Sags), which increases the number of antibodies against the malignant cells and induces a potent T-cell immune response targeted to the tumor antigen. For a stronger immune response, IPF may be paired with different kinds of adjuvants such as IL-2, IL-6, IL-12 or other cytokines. Another form of immunotherapy can also provide active immunization, which allows for amplification of the immune response. In addition, vaccines can generate a memory immune response. Recent advances have revealed that any cellular protein (expressed in virally infected cells or cancer cells) can be recognized by the immune system if those proteins are presented to the immune system in a form that results in an activation rather than ignorance or tolerance to the antigen. In addition, T-cells rather than B-cells are usually responsible for this recognition.

It is important to point out that when we discuss vaccines for cancer we are referring to treatment rather than prevention, because the antigens expressed by tumor cells (which are the immunogens recognized by the immune system) are not yet known. Attaching known proteins will increase the number of antibodies to fight against them.

This mechanism of action will give us an exact answer (known antigens we have to make known for immune system). In contrast we can use vaccines to prevent infectious diseases because the antigens expressed the causative agent - fraction and/or its proteins that can attach, serve as the immunogen are already known.

About Cantech Holding, Inc. (f/k/a Reve Technologies, Inc.)

The Company was incorporated on May 11, 2010 (Date of Inception) under the laws of the State of Nevada, as Bassline Productions, Inc. On March 21, 2014 the Company amended its articles of incorporation and changed its name to Reve Technologies, Inc. and investing to develop and market emerging hardware, mobile and web applications later establishing a new Capital Purchase Division. The Company is now a transitioning forward with the acquisition of an Exclusive License Agreement for Patented Technology for Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico with privately held immune-oncology and Therapeutics company. Through the terms for the Company's Exclusive Sub Licensing Agreement with Canteck Pharma, Inc. we will focus on the development, manufacture and commercialize our lead product Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico.

This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Reve Technologies, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Reve Technologies, Inc.'s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Reve Technologies, Inc.'s filings with the Securities and Exchange Commission.

Public Relations and Shareholder Information

Name: Dennis Alexander
Phone: (602) 326-7371
Email: revestechnology1@gmail.com

SOURCE: Cantech Holding, Inc.